TP53 and acute myeloid leukemia: These MEP-associated AML subtypes exhibit resistance to conventional chemotherapy and dismal survival rates, primarily attributed to BCL-XL-mediated survival mechanisms and recurrent TP53/IDH1 genetic alterations, highlighting the urgent need for BCL-XL-targeted agents and combined immunotherapeutic regimens to enhance clinical outcomes [22,23].